Clinical Trial Search

Primary: Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA — 60.5; 30.0; 45.2; 27.3 percentage of subjects with ≥ 15 letters

Primary: Change in Slope of First Morning Urinary PCR From the 8-week RAAS Blocker run-in Period to the 12-week CCX168 Treatment Period — -2.4; 15.3; -23.9 mg/g/week — p=0.965

Primary: Number of Participants With Dose Limiting Toxicities — 0 Participants

Primary: Percent Reduction in EASI Score From Baseline to Week 16 — 57.56; 63.03; 63.50; 39.67 percent reduction from Baseline — p=0.0007

Primary: Sensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds — 100; 100; 100; 100 percentage of participants

Primary: NIMH Symptom Severity Scale (for TTM or Skin Picking) — -1.19; -6.98 units on a scale

Primary: Surgeon Predicted Use of Fluorescein Sodium in Future Cases — 0; 0; 4; 3 participants

Primary: Change in Absolute Gluconeogenesis From Baseline to 12 Weeks — 0.018; -0.050 mg/kg LBM/min

Primary: Revised Fibromyalgia Impact Questionnaire (FIQ-R) Total Score — -8.7; -3.0 score on a scale

Primary: Intra-reader Difference of Summed Rest Score (SRS) for Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) — 6.662; 6.513; 6.235; 6.219 score on a…

Primary: Win Ratio of Composite Endpoint — 228; 206 Number of Wins for the group

Primary: Change in the Rate of Adverse Cosmesis (Defined as Fair or Poor Cosmesis) Compared to Baseline Using the Harvard Cosmetic Rating: — 2; 0; 0 Participants

Primary: Number of Participants With Relapsed Leukemia — 3; 5 Participants

Primary: Change From Baseline in Mean Seated Systolic BP (SBP) — -16.6; -17.0; -16.0; -19.8 mmHg

Primary: World Health Organization (WHO) Ordinal Scale Score — 26; 22; 1; 2 Participants